ODAIA Raises Series C to Scale Predictive Commercial Intelligence for Pharma

Returning investors and strategic investor PHM back
ODAIA’s next stage of growth

BOSTON, Nov. 17, 2026 — ODAIA, an AI company delivering predictive commercial intelligence for pharma, today announced it has closed a US$15 million Series C financing led by Monograph Capital and anchored by strategic investor PHM, the leading health media agency in the U.S., part of Publicis Groupe. Investors from ODAIA’s earlier rounds are also returning: BDC Capital, Flint Capital, Innospark Ventures, and Graphite Ventures from its Series A and Threshold Ventures and Wittington Ventures from its Series B. ODAIA will use the capital to grow within the enterprise pharma accounts it already serves and continue innovating its commercial intelligence platform.

Leading biopharmaceutical companies use ODAIA for commercial intelligence and workflow automations for field and marketing teams across many therapeutic areas. ODAIA predicts patient journeys, uncovers missed Rx opportunities, determines which healthcare professionals (HCPs) to prioritize through which channels, and keeps sales and marketing working from one brand strategy.

“Pharma has proven that AI works in commercial. The hard part now is scaling it,” said Philip Poulidis, CEO and co-founder of ODAIA. “Most companies can show results on one brand, and every new brand or therapeutic area still costs another team and another build. ODAIA started by helping field teams decide where to focus. Today our platform is the commercial intelligence infrastructure that scales what’s working across brand, marketing, and field teams, and across a company’s whole portfolio. This round lets us go deeper with the enterprise customers we already serve and, with PHM, bring that infrastructure to more of the industry, faster.”

“We have watched the ODAIA team turn predictive AI into decisions that pharma brand and field teams act on every day,” said Charles Conn, co-founder and partner at Monograph Capital, which co-led ODAIA’s Series B and led this round. “The ODAIA team has a track record of helping large and specialty pharma brands reach the physicians whose patients need their therapies most.”

One strategy for brand, field, and marketing

Inside most pharma companies, data sits in many systems owned by separate teams, so brand, marketing, and field each work from a different picture of the same physician. Patients get missed, field and digital effort lands in the wrong places, and nobody can say with confidence what is influencing HCP decisions. ODAIA’s commercial intelligence platform provides the foundation underneath. It brings disparate data, field sales activity, and digital engagement into one view of each HCP that brand, marketing, and field teams all work from.

Brand teams codify their strategy once in Brand Strategy Studio, and ODAIA’s decision engines turn it into HCP-level choices about who to reach, through which channel, when, and with what message. Extending to a new brand or therapeutic area is a matter of configuration. The platform identifies physicians whose patients are likely to need a therapy, often months before a diagnosis shows up in the data. Field Intelligence delivers prioritized call plans to field teams inside their CRM, and Marketing Intelligence orchestrates individualized HCP journeys across digital and partner channels.

Every ODAIA recommendation comes with the reasoning behind it, so commercial and compliance teams can see why. Commercial leaders ask questions of their data in plain language and get finished analysis in minutes. The platform continuously measures engagement and prescription lift and feeds the results into the next decision, so teams can adjust as markets change.

Alongside the financing, ODAIA signed a commercial Platform Agreement that makes PHM, Publicis Groupe’s U.S. health media agency, ODAIA’s exclusive agency partner in the U.S.

ODAIA continues to work directly with pharma companies, and its platform works alongside the CRM, in-house analytics models, and data infrastructure each brand already uses. The partnership connects signals across digital media and field sales so clients can coordinate HCP engagement across both.

Founded out of the University of Toronto in 2018, ODAIA is headquartered in Toronto with an office in Boston. To learn more about ODAIA’s commercial intelligence platform, visit odaia.ai.

About ODAIA
ODAIA is the leading AI company delivering predictive commercial intelligence for pharma. Leading biopharmaceutical companies, from top-20 global organizations to specialty innovators, use ODAIA to uncover missed Rx opportunities, determine which HCPs to prioritize through which channels, and coordinate true omnichannel execution across sales and marketing. By continuously turning HCP and patient signals into real-time actions, ODAIA enables commercial teams to adapt strategy as markets change and activate updated guidance directly within the systems they already use. Learn more at odaia.ai.

SOURCE ODAIA

Leave a Reply

Your email address will not be published. Required fields are marked *